You searched for "prostatic"

471 results found

Richard Wolf Range Update

Richard Wolf a global business with headquarters in Germany and over a century of tradition and expertise in the field of endoscopy. We develop, manufacture and market specific system solutions for minimally invasive human medicine.

An update on erectile dysfunction guidelines and treatment options

Erectile dysfunction is defined as the persistent inability to attain and / or maintain an erection sufficient for sexual performance. Not only does this have a psychosocial impact, it also affects the quality of life of both the patients and...

Impact of MetS on prostate cancer (PCa)

Metabolic syndrome is associated with an increased risk of finding prostate cancer (PCa) overall and high-grade disease on biopsy. The first objective was to determine if MetS is associated with higher final PCa stage and grade on radical prostatectomy (RP)...

The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy

Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...

Read all about it Mar/Apr 2015

It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...

Oncological Imaging: Urology

Imaging updates on renal tumours, urothelial tumours, prostate, adrenal and retroperitoneal tumours are all covered in this text. Whilst aspects relating to prostate imaging are probably covered better elsewhere, what remains is a decent account nicely contained within a single...

Rectal swab guided antibiotics for TRUS biopsy

This is a single centre retrospective study to examine the effect of rectal swab culture-directed prophylaxis on the incidence of prostate biopsy associated infections. Secondary objectives were to determine the rate of fluoroquinolone resistance and extended-spectrum beta-lactamase production in local...

Patient-reported outcomes after prostate cancer treatment

This study used the survivorship (LIVESTRONG) care plan tool to identify patient-reported toxicities that occurred following treatment for prostate cancer. All patients had undergone treatments, which were considered to have similar oncological endpoints. The tool asked patients questions with regard...

Factors and time to conversion from prostate cancer active surveillance to treatment

Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...

The value of Urolink: an OOPE experience

I was fortunate enough to be able to take some time out of my training after ST5 to pursue an Out Of Programme Experience (OOPE) year. During the Urolink meeting at the British Association of Urological Surgeons (BAUS) 2017 conference...

Read all about it May/Jun 2018

It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...